Biotech Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom July 22, 2026
Biotech Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock July 21, 2026
Biotech Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026 July 21, 2026
Biotech ZYUS Announces Database Lock for its Phase 2a UTOPIA-1 Trial, CFO Transition and Continuous Disclosure Update July 20, 2026
Biotech Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D. July 20, 2026
Biotech 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population July 18, 2026
Biotech REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting July 18, 2026